Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P42285
UPID:
MTREX_HUMAN
Alternative names:
ATP-dependent RNA helicase DOB1; ATP-dependent RNA helicase SKIV2L2; Superkiller viralicidic activity 2-like 2; TRAMP-like complex helicase
Alternative UPACC:
P42285; Q2M386; Q6MZZ8; Q6P170; Q8N5R0; Q8TAG2
Background:
Exosome RNA helicase MTR4, also known as ATP-dependent RNA helicase DOB1, plays a pivotal role in RNA metabolism. It catalyzes the ATP-dependent unwinding of RNA duplexes, essential for the degradation of RNA in eukaryotic nuclei. MTR4 is a central subunit in several protein complexes, including TRAMP-like, NEXT, and PAXT, which are crucial for the surveillance and turnover of aberrant transcripts and non-coding RNAs.
Therapeutic significance:
Understanding the role of Exosome RNA helicase MTR4 could open doors to potential therapeutic strategies.